PharmiWeb.com - Global Pharma News & Resources
18-Jun-2019

Pharmacovigilance Market Size is Projected to Jump USD 10.6 Billion by 2026

Global Pharmacovigilance Market Size is expected to reach USD 10.6 Billion by 2026 and growing CAGR around 12.8 % during the forecast period.

The global Pharmacovigilance Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2019 to 2026. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2019 to 2026.

Request a Sample Copy of this Research Report at https://www.acumenresearchandconsulting.com/request-sample/1331

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the global Pharmacovigilance Market.

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market.

The market is studied for regions such as North America (U.S., and Canada), Europe (U.K., Germany, France, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East amp; Africa (GCC, South Africa, and Rest of Middle East amp; Africa).

Key Takeaways:

  • What is the market size in 2018 and the growth rate of the global Pharmacovigilance Market market?
  • What is the market drivers, restrains, opportunities governing the global Pharmacovigilance Market Market?
  • Which is the largest and the fastest growing segments in the global Pharmacovigilance Market market?
  • Who are the key players operating in the market and their market position?
  • What is the pipeline scenario, drug pricing analysis and technological development in the market?

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1331

Market Players:

The Pharmacovigilance market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are Clinquest Group, IBM Corporation, ArisGlobal, ICON plc. Accenture, Clinquest Group B.V., Cognizant, Laboratory Corporation of America Holdings. TAKE Solutions Ltd., PAREXEL International Corporation, BioClinica, Wipro Ltd. and United BioSource Corporation, Capgemini, iMEDGlobal, Foresight Group International AG., among others.

The Major Market Segments of GlobalPharmacovigilance Marketare as below:

Market Segmentation

Market, by Clinical Trial Phase

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Market, by Service

  • In-house
  • Contract Outsourcing

Market, by Type

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Market, by End Use

  • Hospitals
  • Research Organizations
  • Industrial

Market, by Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

The market research study on Pharmacovigilance Market (By Clinical Trial Phase: Pre-clinical, Phase I, Phase II, Phase III, Phase IV; By Service: In-house, Contract Outsourcing; By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining; By End Use: Hospitals, Research Organizations, Industrial) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026 offers detailed insights on global Pharmacovigilance market segments with market dynamics and their impact. The report also covers basic technology development policies.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Pharmacovigilance
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Pharmacovigilance Market By Clinical Trial Phase
1.2.2.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By Clinical Trial Phase (2015-2026)
1.2.2.2. Global Pharmacovigilance Market Revenue Share By Clinical Trial Phase in 2017
1.2.2.3. Pre-clinical
1.2.2.4. Phase I
1.2.2.5. Phase II
1.2.2.6. Phase III
1.2.2.7. Phase IV
1.2.3. Pharmacovigilance Market By Service
1.2.3.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By Service (2015-2026)
1.2.3.2. Global Pharmacovigilance Market Revenue Share By Service in 2017
1.2.3.3. In-house
1.2.3.4. Contract Outsourcing
1.2.4. Pharmacovigilance Market By Type
1.2.4.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.4.2. Global Pharmacovigilance Market Revenue Share By Type in 2017
1.2.4.3. Spontaneous Reporting
1.2.4.4. Intensified ADR Reporting
1.2.4.5. Targeted Spontaneous Reporting
1.2.4.6. Cohort Event Monitoring
1.2.4.7. EHR Mining
1.2.5. Pharmacovigilance Market By End Use
1.2.5.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.2.5.2. Global Pharmacovigilance Market Revenue Share By End Use in 2017
1.2.5.3. Hospitals
1.2.5.4. Research Organizations
1.2.5.5. Industrial
1.2.6. Pharmacovigilance Market by Geography
1.2.6.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Pharmacovigilance Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Pharmacovigilance Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Pharmacovigilance Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Pharmacovigilance Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Pharmacovigilance Major Manufacturers in 2017

CHAPTER 4. Pharmacovigilance Market By Clinical Trial Phase

4.1. Global Pharmacovigilance Revenue By Clinical Trial Phase
4.2. Pre-clinical
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Phase I
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Phase II
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Phase III
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Phase IV
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. Pharmacovigilance Market By Service

5.1. Global Pharmacovigilance Revenue By Service
5.2. In-house
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Contract Outsourcing
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. Pharmacovigilance Market By Type

6.1. Global Pharmacovigilance Revenue By Type
6.2. Spontaneous Reporting
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Intensified ADR Reporting
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Targeted Spontaneous Reporting
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Cohort Event Monitoring
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. EHR Mining
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. Pharmacovigilance Market By End Use

7.1. Global Pharmacovigilance Revenue By End Use
7.2. Hospitals
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Research Organizations
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Industrial
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. North America Pharmacovigilance Market By Country

8.1. North America Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Pharmacovigilance Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. U.S.
8.3.1. U.S. Pharmacovigilance Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)

CHAPTER 9. Europe Pharmacovigilance Market By Country

9.1. Europe Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Pharmacovigilance Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)

CHAPTER 10. Asia-Pacific Pharmacovigilance Market By Country

10.1. Asia-Pacific Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Pharmacovigilance Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.6.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.6.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.7.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.7.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.8.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.8.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)

CHAPTER 11. Latin America Pharmacovigilance Market By Country

11.1. Latin America Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Pharmacovigilance Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)

CHAPTER 12. Middle East Pharmacovigilance Market By Country

12.1. Middle East Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Pharmacovigilance Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)

CHAPTER 13. Africa Pharmacovigilance Market By Country

13.1. Africa Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Pharmacovigilance Market Revenue Share Comparison, 2015 amp; 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
13.3.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
13.3.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
13.4.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
13.4.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
13.5.3. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
13.5.4. Market Revenue and Forecast By End Use, 2015 - 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. Clinquest Group
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. IBM Corporation
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. ArisGlobal
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. ICON plc.
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Accenture
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Clinquest Group B.V.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Cognizant
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Laboratory Corporation
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. TAKE Solutions Ltd.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. PAREXEL International Corporation
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
14.11. BioClinica
14.11.1. Company Snapshot
14.11.2. Overview
14.11.3. Financial Overview
14.11.4. Product Portfolio
14.11.5. Key Developments
14.11.6. Strategies
14.12. Wipro Ltd.
14.12.1. Company Snapshot
14.12.2. Overview
14.12.3. Financial Overview
14.12.4. Product Portfolio
14.12.5. Key Developments
14.12.6. Strategies
14.13. United BioSource Corporation
14.13.1. Company Snapshot
14.13.2. Overview
14.13.3. Financial Overview
14.13.4. Product Portfolio
14.13.5. Key Developments
14.13.6. Strategies
14.14. Capgemini
14.14.1. Company Snapshot
14.14.2. Overview
14.14.3. Financial Overview
14.14.4. Product Portfolio
14.14.5. Key Developments
14.14.6. Strategies
14.15. iMEDGlobal
14.15.1. Company Snapshot
14.15.2. Overview
14.15.3. Financial Overview
14.15.4. Product Portfolio
14.15.5. Key Developments
14.15.6. Strategies
14.16. Foresight Group International AG.
14.16.1. Company Snapshot
14.16.2. Overview
14.16.3. Financial Overview
14.16.4. Product Portfolio
14.16.5. Key Developments
14.16.6. Strategies
14.17. Others
14.17.1. Company Snapshot
14.17.2. Overview
14.17.3. Financial Overview
14.17.4. Product Portfolio
14.17.5. Key Developments
14.17.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1331

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 18-Jun-2019